Sr Director, In Vivo Pharmacology

Earli tackles the #1 problem in the $100B cancer drug market: systemic toxicity. On-target/off-tumor effects force suboptimal dosing, reduced efficacy and sidelining some of the most potent drug classes such as cytokines. Earli’s BioAI approach flips this paradigm:
Drugs are produced only where needed—
in the tumor,
by the tumor,
against the tumor. Cancer cells become their own drug factories, enabling localized immune activation, even in cold tumors.

This was enabled by three core innovations:

Together, these technologies create a new biological control layer, allowing tumors to self-identify and trigger their own targeted immune attack—achieving specificity beyond current targeted or IO therapies.

Earli plans to enter the clinic by mid-2027 with a Phase 1/2 lung cancer trial. The company is backed by a16z, Khosla, Perceptive, Alex Gorsky, Marc Benioff, Breyer, Emerson Collective, Sands Capital and others. The SAB includes Jim Allison (Nobel Laureate, MD Anderson), Bob Langer (Co-founder Moderna, MIT), Phil Greenberg (Co-founder Juno), Amy Abernethy (frm. Principal Deputy FDA Commissioner), Bill Hait (former J&J EVP Oncology R&D), and Alan Ashworth (President UCSF Cancer Center).

The leadership team brings deep gene therapy, LNP, CMC and tech experience; CEO ++Cyriac Roeding++ previously led a $250M (11x return) exit.

• You share our same sense of dedication, scientific passion and entrepreneurial spirit
• You work well in a fast-paced and extremely focused startup environment
• You are not only smart, but clever and constantly think outside the box
• You are able to make logical decisions in an instant when there is little time to evaluate
• You are a natural communicator and relationship builder
• You stay calm under high pressure and stress
• You have the ability to multi-task in a serious way, with an extreme attention to detail
• You become a representative of the core DNA of the company through who you are

Earli is currently seeking a Senior Director, In Vivo Pharmacology to oversee and lead the In vivo/Translational biology group. The successful candidate will have a proven track record of successfully initiating and advancing pharmacology and translational science projects across oncology indications from Discovery through IND enabling studies and beyond. She/he will be responsible for working with company scientific leadership for the design and planning of in vivo preclinical studies to characterize the efficacy, PK/PD and safety of Earli’s drug candidates.

This position will report to the SVP of Platform R&D.

• Oversee and manage the In vivo/Translational Biology group at Earli to support the growth and expansion of the team
• Develop preclinical strategy for advancing Earli’s candidate pipeline in immuno-oncology, including selection of appropriate in vivo models, efficacy, safety, PK/PD characterization, and development of translational biomarkers to support FIH clinical studies
• Help lead operational planning and oversight of internal and external in vivo studies
• Be the key stakeholder to select and oversee CROs to conduct external non-GLP and GLP safety and toxicology studies
• Help author nonclinical sections of regulatory filings, including the production of high-quality technical reports including statistical analyses and data integrity review for these filings
• Proactively foster the growth of team members and identify opportunities for staff to…